Lineage Cell Therapeutics, Inc. (LCTX) vs X4 Pharmaceuticals, Inc. (XFOR)
- Lineage Cell Therapeutics, Inc. LCTX 0.98 −1.01%
- X4 Pharmaceuticals, Inc. XFOR 2.59 −1.89%
Lineage Cell Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($261.8M and $250.5M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −51.7%. Lineage Cell Therapeutics, Inc. has the higher net margin (−246.6% vs −568.8%) and the higher return on invested capital (−186.8% vs −226.6%). Across the 17 metrics below, Lineage Cell Therapeutics, Inc. leads on 11 and X4 Pharmaceuticals, Inc. on 6.
Valuation
Profitability
| Metric | LCTX | XFOR | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.46% | 81.51% | 65.16% |
| Operating margin | (205.23%) | (554.71%) | 0.00% |
| Net margin | (246.58%) | (568.80%) | 0.00% |
| Free cash flow margin | (186.43%) | (559.95%) | 0.00% |
| Return on equity | (60.35%) | (113.08%) | (56.36%) |
| Return on assets | (32.75%) | (50.32%) | (48.04%) |
| Return on invested capital | (186.79%) | (226.62%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack